Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT06260449
Other study ID # Trematode
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date October 21, 2023
Est. completion date December 21, 2024

Study information

Verified date February 2024
Source Assiut University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Different Treatment Approaches of Presumed Trematode-Induced Uveitis including periocular injection and medical treatment Nd laser treatment


Description:

Uveitis, characterized by inflammation of the uvea, is a complex and potentially sight-threatening ocular condition that can result from various etiologies. Among causes of uveitis, trematode-induced uveitis represents a distinct and intriguing subset characterized by the presence of a single or multiple pearl like nodules in the anterior chamber (AC) or less commonly in the conjunctive, cornea or even in the ciliary body and posterior segment. Trematodes, or parasitic flatworms, have been implicated in causing uveitis through the migration of larvae or adult worms into the eye, triggering an inflammatory response 1. Despite its rarity, trematode-induced uveitis poses diagnostic and therapeutic challenges due to the diversity of trematode species and the lack of standardized treatment protocols 2. The treatment of trematode-induced uveitis typically involves addressing the underlying parasitic infection and managing the associated inflammation. Various treatment modalities have been reported in literature. Antiparasitic medications have been tried by some authors. Advantages include targeting the underlying cause by killing the parasites. In addition, systemic medications can reach distant sites of infection However, there is no evidence that the parasite is actually living in ocular tissues and the inflammatory process may be directed against already dead parasite 3. Also, they may have side effects. Effectiveness depends on the specific type of trematode and its susceptibility to the chosen medication. Steroid Therapy is considered the gold standard treatment including topical steroids and periocular Injection of Triamcinolone) Advantages: Reduces inflammation in the eye. Provides symptomatic relief. Disadvantages: Does not address the underlying cause (parasitic infection)4. Prolonged or high-dose steroid use may lead to side effects, such as increased intraocular pressure or cataract formation. In resistant cases Surgery has been advocated by many authors Advantages: Surgical removal of nodules may be considered in specific cases. Can be beneficial in cases of severe complications, such as retinal detachment5. Disadvantages: Invasive procedure with associated risks and is mainly aimed at managing complications. Laser Therapy has been reported to destroy the pearl like nodules using Argon laser Potential damage to surrounding healthy tissue is the main drawback. Therefore, there is no consensus about the best line of treatment for this entity Rational for this study: Understanding the available treatment options is crucial for healthcare professionals involved in the care of patients with this condition7


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 31
Est. completion date December 21, 2024
Est. primary completion date October 21, 2024
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: Clinical Presentation: Presence of Uveitis: Include patients with clinically diagnosed uveitis, characterized by inflammation of the uvea9. Suspicion of Trematode Etiology: Include cases where there is a reasonable suspicion or evidence suggesting trematode-induced uveitis based on clinical picture of pearl like whitish AC or subconjunctival nodules characteristic for this specific entity, history of swimming in local ponds and canals in endemic areas.10 Diagnostic Confirmation: Positive Diagnostic Findings: Include patients with characteristic clinical picture and exclusion of other causes of granulomatous uveitis by appropriate laboratory tests and imaging modalities.11 Severity of Uveitis: Disease scores at presentation for parasitic granulomatous uveitis Parameter range score Diameter of AC lesion >3mm 1 3-5mm 2 <5mm 3 Grade of AC inflammation +.5 to+1 1 - 2 to +3 2 - 4 3 Complications at presentation none 0 Retro corneal scar or corectopia 1 Cataract 2 Glaucomatous optic atrophy 3 Eyes with scores > 5 were started on steroid therapy. Patients with severity scores <= 5at presentation were advised for surgical excision of the AC lesions. Based on SUN grading scheme for AC cells. Age and Gender: All Ages: Consider including patients of all age groups. Both Genders: Include both males and females Exclusion Criteria: Alternative Diagnoses: Presence of Other Ocular Diseases: Exclude patients with other causes of uveitis12. Concomitant Systemic Infections: Exclude patients with concomitant systemic infections that may independently cause uveitis. Patients unwilling to participate in the study Treatment History: Previous Treatment for Trematode-Induced Uveitis: Exclude patients who have previously undergone treatment specifically for trematode-induced uveitis13. Non-Compliance: Exclude patients with a history of non-compliance with prescribed treatments. Contraindications to Specific Treatments: Contraindications to Medications: Exclude patients with known contraindications to specific antiparasitic medications or corticosteroids. Ineligibility for Surgery: Exclude patients who are not suitable candidates for surgical interventions14. Pregnancy and Lactation: Pregnant or Lactating Women: Consider excluding pregnant or lactating women due to potential risks associated with certain treatments15

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Surgical removal
Removal of the granuloma

Locations

Country Name City State
Egypt Assiut Assiut

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

References & Publications (3)

Amin RH, Abdullatif AM. Management of presumed trematode-induced granulomatous intermediate uveitis. Eye (Lond). 2023 Aug;37(11):2299-2304. doi: 10.1038/s41433-022-02336-4. Epub 2022 Dec 7. — View Citation

Amin RM, Radwan AE, Goweida MB, El Goweini HF, Bedda AM, Lotfy WM, Ahmed ARH. Management of presumed trematode induced granulomatous uveitis in pediatric patients. Jpn J Ophthalmol. 2019 Jan;63(1):119-125. doi: 10.1007/s10384-018-0632-3. Epub 2018 Nov 2. — View Citation

El Hefny E, Sabry D, Sewelam A, El Nokrashy A. Characteristics of Childhood Presumed Trematode-Induced Granulomatous Anterior Uveitis Using Ultrasound Biomicroscopy. Ocul Immunol Inflamm. 2022 Oct-Nov;30(7-8):1604-1608. doi: 10.1080/09273948.2021.1922709. Epub 2021 May 20. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Surgical removal Surgical wash of granuloma with topical and systemic steroid Baseline
See also
  Status Clinical Trial Phase
Recruiting NCT04101604 - Biomarkers of Common Eye Diseases
Active, not recruiting NCT04704609 - Imaging Quantification of Inflammation (IQI)
Completed NCT03173144 - Chronic Inflammatory Disease, Lifestyle and Treatment Response
Withdrawn NCT01280669 - Intravitreal Sirolimus as Therapeutic Approach to Uveitis Phase 2
Terminated NCT02907814 - Measurement of Anterior Chamber Cell Grading Using Ocular Coherence Tomography N/A
Active, not recruiting NCT02252328 - Use of Simvastatin as a Steroid Sparing Agent for Uveitis Patients Phase 2/Phase 3
Completed NCT04183387 - Simvastatin in Uveitis Phase 2
Completed NCT01983488 - Clinical Outcome in Uveitis
Withdrawn NCT00499551 - A Phase I/IIa Study for the Treatment of Uveitis With Iontophoresis Phase 1/Phase 2
Completed NCT00476593 - Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications N/A
Completed NCT00132691 - Multicenter Uveitis Steroid Treatment (MUST) Trial Phase 4
Terminated NCT00114062 - Study to Treat Uveitis Associated Macular Edema Phase 2
Completed NCT00001867 - Effect of Pregnancy on Uveitis N/A
Completed NCT00379275 - Eye and Immunogenetic Features of Sarcoidosis N/A
Active, not recruiting NCT03828019 - Adalimumab vs. Conventional Immunosuppression for Uveitis Trial Phase 3
Terminated NCT01939691 - Macular Edema Nepafenac vs. Difluprednate Uveitis Trial Phase 4
Active, not recruiting NCT03889860 - Objective Choroidal Thickness Measurements in Uveitis
Completed NCT00070759 - Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis Phase 2
Recruiting NCT05486468 - The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment Phase 3
Active, not recruiting NCT05385757 - UNICORNS: Uveitis in Childhood Prospective National Cohort Study